ALS: the French Research Agency supports Neurophoenix

As part of the French National Research Agency (ANR) generic call for proposals 2020, Neurophoenix, in collaboration with Institut Pasteur ( Viral Neuro-Immunology laboratory) and the Brain Institute (“ALS : causes and mechanisms of motor neuron degeneration” team), has obtained a PRCE funding to study the neuroprotective and anti-inflammatory properties of its technology for the treatment of amyotrophic lateral sclerosis (ALS), also known as Charcot’s disease.

ALS is a neurodegenerative and neuroinflammatory disease that gradually destroys motor neurons inducing progressive muscle paralysis and which quickly becomes fatal when the respiratory muscles are affected. In France, this pathology now affects 5 to 7,000 patients with an annual incidence of close to 2.5 per 100,000 inhabitants.